This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Ferrous cysteine glycinate is an ingredient found in a variety of supplements and vitamins.
- Brand Names
- EnBrace HR, EnLyte
- Generic Name
- Ferrous cysteine glycinate
- DrugBank Accession Number
- DB11197
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Ferrous cysteine glycinate (DB11197)
- Weight
- Average: 371.2
Monoisotopic: 370.990814 - Chemical Formula
- C8H17FeN3O6S2
- Synonyms
- Ferrous cysteine glycinate chelate (1:2:1)
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Ferrous cation ionic GW89581OWR 15438-31-0 CWYNVVGOOAEACU-UHFFFAOYSA-N - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image PramLyte Ferrous cysteine glycinate (13.6 mg/1) + 1,2-docosahexanoyl-sn-glycero-3-phosphoserine calcium (6.4 mg/1) + 1,2-icosapentoyl-sn-glycero-3-phosphoserine calcium (800 ug/1) + Betaine (500 ug/1) + Citric acid monohydrate (1.83 mg/1) + Cobamamide (50 ug/1) + Cocarboxylase (25 ug/1) + Escitalopram oxalate (10 mg/1) + Flavin adenine dinucleotide (25 ug/1) + Folic acid (1 mg/1) + Leucovorin (2.5 mg/1) + Levomefolate magnesium (7 mg/1) + Magnesium ascorbate (24 mg/1) + NADH (25 ug/1) + Phosphatidyl serine (12 mg/1) + Pyridoxal phosphate (25 ug/1) + Sodium citrate (3.67 mg/1) + Zinc ascorbate (1 mg/1) Kit Oral Allegis Pharmaceuticals, LLC 2015-09-11 2016-01-04 US 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image DermaNIC Ferrous cysteine glycinate (1.5 mg/1) + Acetylcysteine zinc (69.5 mg/1) + Chromium nicotinate (0.57 mg/1) + Folic acid (500 ug/1) + Hydroxocobalamin (15 ug/1) + Inositol nicotinate (328 mg/1) + Niacin (1.5 mg/1) + Nicotinamide (498 mg/1) Tablet Oral Allegis Pharmaceuticals, LLC 2014-02-03 2016-12-01 US EnBrace HR Ferrous cysteine glycinate (13.6 mg/1) + 1,2-docosahexanoyl-sn-glycero-3-phosphoserine calcium (6.4 mg/1) + 1,2-icosapentoyl-sn-glycero-3-phosphoserine calcium (800 ug/1) + Betaine (500 ug/1) + Cobamamide (50 ug/1) + Cocarboxylase (25 ug/1) + Flavin adenine dinucleotide (25 ug/1) + Folic acid (1 mg/1) + Magnesium L-threonate (1 mg/1) + Leucovorin (2.5 mg/1) + Levomefolate magnesium (5.23 mg/1) + Magnesium ascorbate (24 mg/1) + NADH (25 ug/1) + Phosphatidyl serine (12 mg/1) + Pyridoxal phosphate (25 ug/1) + Zinc ascorbate (1 mg/1) Capsule, delayed release pellets Oral Jaymac Pharma 2011-08-12 Not applicable US Escavite D Ferrous cysteine glycinate (6 mg/1) + Ascorbic acid (100 mg/1) + Beta carotene (2500 [iU]/1) + Biotin (45 ug/1) + Cholecalciferol (600 [iU]/1) + Cupric oxide (2 mg/1) + DL-alpha-Tocopherol (30 [iU]/1) + Folic acid (400 ug/1) + Hydroxocobalamin (6 ug/1) + Magnesium oxide (60 mg/1) + Niacin (20 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxine hydrochloride (2 mg/1) + Riboflavin (1.7 mg/1) + Sodium fluoride (0.25 mg/1) + Thiamine hydrochloride (1.5 mg/1) + Zinc oxide (15 mg/1) Tablet, chewable Oral GM Pharmaceuticals, INC 2014-03-03 2018-11-01 US Escavite Lq Ferrous cysteine glycinate (1 mg/1mL) + Ascorbic acid (35 mg/1mL) + Cholecalciferol (400 [iU]/1mL) + Cyanocobalamin (0.9 ug/1mL) + D-alpha-Tocopherol acetate (7.5 [iU]/1mL) + Ferric pyrophosphate (5 mg/1mL) + Niacin (8 mg/1mL) + Pyridoxine hydrochloride (0.4 mg/1mL) + Riboflavin (0.6 mg/1mL) + Sodium fluoride (0.25 mg/1mL) + Thiamine hydrochloride (0.5 mg/1mL) + Vitamin A palmitate (1500 [iU]/1mL) Liquid Oral GM Pharmaceuticals, INC 2013-08-20 2018-10-03 US
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 8B4OP7RK5N
- CAS number
- Not Available
- InChI Key
- NIBOCUPOPAKNJE-NVKWYWNSSA-L
- InChI
- InChI=1S/2C3H7NO2S.C2H5NO2.Fe/c2*4-2(1-7)3(5)6;3-1-2(4)5;/h2*2,7H,1,4H2,(H,5,6);1,3H2,(H,4,5);/q;;;+2/p-2/t2*2-;;/m00../s1
- IUPAC Name
- lambda2-iron(2+) (2R)-2-amino-3-sulfanylpropanoic acid 2-aminoacetic acid (2R)-2-amino-3-sulfanidylpropanoate
- SMILES
- [Fe++].NCC(O)=O.[H][C@](N)(CS)C(O)=O.[H][C@](N)(C[S-])C([O-])=O
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Withdrawn Treatment Menstrual Related Mood Disorder / Premenstrual Dysphoric Disorder (PMDD) / Premenstrual Syndrome (PMS) / Premenstrual tension with edema 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral Capsule, liquid filled Oral Capsule, delayed release pellets Oral Tablet, chewable Oral Liquid Oral Kit Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 23.1 mg/mL ALOGPS logP -2.6 ALOGPS logP -2.8 Chemaxon logS -0.72 ALOGPS pKa (Strongest Acidic) 2.35 Chemaxon pKa (Strongest Basic) 9.05 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 66.15 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 39.8 m3·mol-1 Chemaxon Polarizability 10.67 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at December 03, 2015 16:51 / Updated at September 28, 2021 21:54